Philogen SpA
MIL:PHIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Philogen SpA
Total Equity
Philogen SpA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Philogen SpA
MIL:PHIL
|
Total Equity
€138.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Genenta Science SPA
NASDAQ:GNTA
|
Total Equity
€12.5m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Ulisse Biomed Spa
MIL:UBM
|
Total Equity
€23.7m
|
CAGR 3-Years
48%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
Philogen SpA
Glance View
Philogen SpA engages engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 135 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The firm's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
See Also
What is Philogen SpA's Total Equity?
Total Equity
138.7m
EUR
Based on the financial report for Dec 31, 2024, Philogen SpA's Total Equity amounts to 138.7m EUR.
What is Philogen SpA's Total Equity growth rate?
Total Equity CAGR 5Y
15%
Over the last year, the Total Equity growth was 53%. The average annual Total Equity growth rates for Philogen SpA have been 10% over the past three years , 15% over the past five years .
